Repositorio Dspace

Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study

Mostrar el registro sencillo del ítem

dc.contributor.author Llurba, Elisa
dc.contributor.author Crispi, Fatima
dc.contributor.author Crovetto, Francesca
dc.contributor.author Youssef, Lina
dc.contributor.author Delgado, Juan-Luis
dc.contributor.author Puig, Isabel
dc.contributor.author Mora, Josefina
dc.contributor.author Krofta, Ladislav
dc.contributor.author Mackova, Katerina
dc.contributor.author Martínez-Varea, Alicia
dc.contributor.author Tubau, Albert
dc.contributor.author Ruiz, Aina
dc.contributor.author Paya, Antoni
dc.contributor.author Prat, María
dc.contributor.author Chantraine, Frederic
dc.contributor.author Comas, Carmina
dc.contributor.author Kajdy, Anna
dc.contributor.author López-Tinajero, María-Fernanda
dc.contributor.author Figueras, Francesc
dc.contributor.author Gratacos, Eduard
dc.date.accessioned 2025-11-20T07:25:22Z
dc.date.available 2025-11-20T07:25:22Z
dc.date.issued 2024-03
dc.identifier.citation Llurba E, Crispi F, Crovetto F, Youssef L, Delgado JL, Puig I, et al. Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study. BMJ Open. marzo de 2024;14(3):e076201.
dc.identifier.issn 2044-6055
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21580
dc.description.abstract INTRODUCTION: Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. METHODS AND ANALYSIS: We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of >90th centile is used to define the high risk of subsequent pre-eclampsia and offer planned delivery from 37 weeks. The efficacy variables will be analysed and compared between groups primarily following an intention-to-treat approach, by ORs and their 95% CI. This value will be computed using a Generalised Linear Mixed Model for binary response (study group as fixed effect and the centre as intercept random effect). ETHICS AND DISSEMINATION: The study is conducted under the principles of Good Clinical Practice. This study was accepted by the Clinical Research Ethics Committee of Hospital Clinic Barcelona on 20 November 2020. Subsequent approval by individual ethical committees and competent authorities was granted. The study results will be published in peer-reviewed journals and disseminated at international conferences. TRIAL REGISTRATION NUMBER: NCT04766866.
dc.language.iso eng
dc.publisher BMJ PUBLISHING GROUP
dc.rights http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.uri Atribución-NoComercial-SinDerivadas 3.0 España *
dc.subject.mesh Infant, Newborn
dc.subject.mesh Pregnancy
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Pre-Eclampsia/diagnosis/prevention & control/epidemiology
dc.subject.mesh Vascular Endothelial Growth Factor Receptor-1
dc.subject.mesh Placenta Growth Factor
dc.subject.mesh Cesarean Section
dc.subject.mesh Biomarkers
dc.subject.mesh Predictive Value of Tests
dc.subject.mesh Randomized Controlled Trials as Topic
dc.subject.mesh Multicenter Studies as Topic
dc.title Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 38458783
dc.relation.publisherversion https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2023-076201
dc.identifier.doi 10.1136/bmjopen-2023-076201
dc.journal.title Bmj Open


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta